March 21, 2025 11:24 AM EDT

AstraZeneca puts $2.5B toward first vaccine factory and second R&D site in China

Anna Brown

News Reporter

AstraZeneca is again boosting its manufacturing footprint in China, this time making a $2.5 billion investment to build its first vaccine plant and second R …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca puts $2.5B toward first vaccine factory and second R&D site in China

Anna Brown

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Trump think tank resurrects international drug pricing model to go after 'global freeloading'

Alnylam hopes its broad ATTR-CM label can give Amvuttra an edge in heart disease

BARDA cancels annual biomedical event for industry, government reps

The buildup to Chimerix's $935M exit to Jazz, with more than half a dozen parties intrigued

Genfit's up to €185M royalty deal; J&J’s Tremfya gets a Crohn's approval

Johnson & Johnson earmarks $55B to boost US capacity

As­traZeneca puts $2.5B to­ward first vac­cine fac­to­ry and sec­ond R&D site in Chi­na

News Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

AstraZeneca puts $2.5B toward first vaccine factory and second R&D site in China